Company Profile
Annexon, Inc. Stock Price, News & Analysis
- Ticker:
- ANNX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.13 USD (-1.72%)
Close
Last updated: July 27, 2026
862M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, ANNX closed down 1.72% at $5.13. No new same-company headline was identified in the current news window.
Company overview
Business overview
Annexon is a neuroscience company focused on complement biology and autoimmune or neuroinflammatory disease. Its platform is built around modulating immune pathways in the nervous system and beyond.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Annexon sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical validation, target biology, and the potential to build a differentiated CNS or immunology franchise.
Position Within the Biotechnology Landscape
Annexon is a platform neuroscience name whose valuation depends on proof-of-concept and mechanism differentiation.
Future catalysts
Annexon has a couple of decisive moments ahead, and they are both the sort of milestones that can move the narrative quickly. ARCHER II in geographic atrophy is headed toward topline data, while tanruprubart has already taken a meaningful step in Europe with the Guillain-Barré filing.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
BCLI · Source: Brainstorm Cell Therapeutics Inc.
- 02
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
DNLI · Source: Denali Therapeutics
- 03
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
TNXP · Source: Tonix Pharmaceuticals
- 04
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
IKT · Source: Inhibikase Therapeutics
- 05
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
KTTA · Source: Pasithea Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Annexon, Inc. (ANNX)?
Annexon, Inc. (ANNX) most recently closed at 5.13 USD, a -1.72% move versus the previous session.
What is the market cap of Annexon, Inc. (ANNX)?
Annexon, Inc. currently has a market capitalization of 862M USD on BioPharmSignal.
What does Annexon, Inc. do?
Annexon is a neuroscience company focused on complement biology and autoimmune or neuroinflammatory disease. Its platform is built around modulating immune pathways in the nervous system and beyond.
On which exchange is ANNX stock listed?
Annexon, Inc. (ANNX) is associated with NASDAQ, United States, Biopharma.
What is Annexon?
Annexon has a couple of decisive moments ahead, and they are both the sort of milestones that can move the narrative quickly.
Which conditions is Annexon, Inc. targeting with Annexon?
Annexon, Inc. is associated with neuroscience based on its company overview and current catalyst commentary.
How does Annexon, Inc. describe recent progress with Annexon?
Annexon has a couple of decisive moments ahead, and they are both the sort of milestones that can move the narrative quickly.
What is Europe?
ARCHER II in geographic atrophy is headed toward topline data, while tanruprubart has already taken a meaningful step in Europe with the Guillain-Barré filing.